Background. The efficiency and mechanisms of adoptive transfer of cytomegalovirus (CMV)specific T cells for refractory CMV infection after haploidentical stem cell transplantation (haplo-SCT) remain largely unknown.
In this study, we prospectively investigated the therapeutic application of donor-derived CMV-specific T cells in 32 patients with refractory and persistent CMV infection after haplo-SCT. We also selected another group of 32 patients with nonrefractory CMV infection after haplo-SCT as control subjects. We analyzed the phenotypic and functional characteristics of CMV-specific T cells and their subsets before and after immunotherapy in the refractory CMV and nonrefractory CMV cohorts. We aimed to (1) evaluate the safety and antiviral activity of CMV-specific T cells for refractory CMV infection in haplo-SCT recipients and (2) identify the mechanisms driving the sustained antiviral immunity that is induced by adoptive T-cell transfer.
PATIENTS, MATERIALS, AND METHODS

Patients and Protocol Design
From December 2015 to August 2016, patients with a hematological malignancy who developed CMV infection within 100 days after haplo-SCT were recruited to participate in the study. The study design is shown in Figure 1 . The inclusion criteria for cellular anti-CMV therapy were as follows: (1) recipients with refractory and persistent CMV infection, (2) an available CMV-seropositive donor and a recipient who agreed to T-cell transfer therapy, (3) successful generation of CMV-specific T cells, and (4) a life expectancy of at least 3 months. The exclusion criteria were as follows: (1) grade 2-4 graft-versus-host disease (GVHD) or serious organ damage within 1 week of cellular therapy, (2) treatment by infusion of donor lymphocytes, (3) response to continuing antiviral therapy before adoptive cellular therapy (that is, the viral load was reduced at least 1 log), and (4) incomplete patient data. A total of 32 consecutive patients who received CMV-specific T-cell transfer were prospectively enrolled in our study. Patients who only transiently responded to cellular therapy (ie, the CMV copy number increased again after decreasing for a short time) received 1 more adoptive T-cell transfer. The primary endpoint was infusion-related toxicities. Patients were closely monitored for acute infusionrelated toxicities for the first 2-4 hours after T-cell transfer and were then monitored for acute and chronic GVHD throughout the observation period.
As reported, patients with nonrefractory and transient CMV reactivation usually have a higher quantity and quality of CMVspecific T cells compared with patients with refractory and persistent CMV infection or without CMV reactivation [15] [16] [17] . Therefore, to assess the recovery of CMV-specific T cells in each treated patient, we selected control subjects at a 1:1 ratio who were matched in terms of age, sex, primary disease, and posttransplant interval ( Figure 1 ). Additionally, 10 age-matched CMV-seropositive healthy donors were also selected as normal control subjects. Written informed consent was obtained from all patients and donors, and this study was approved by the institutional review board of Peking University. Nonrefractory CMV infection (n = 158) Figure 1 . Study design. *Cytomegalovirus (CMV)-specific T cells (CTLs) were not infused for the following reasons: (1) the patient did not agree to the CTL infusion, (2) a CMV-seropositive donor was not available or the generation of CTLs failed, (3) grade 2-4 graft-versus-host disease or serious organ damage was observed at the time of cellular therapy, (4) the patient responded to the continuing antiviral therapy before adoptive cellular therapy (ie, the viral load was reduced >1 log), or (5) the patient was treated by the infusion of donor lymphocytes instead. Abbreviations: CMV, cytomegalovirus; CTL, cytomegalovirus-specific T cell; haplo-SCT, haploidentical stem cell transplantation.
Transplant Protocol and Antiviral Treatment
Haploidentical transplant protocols, including conditioning, mobilization, and collection of stem cells, and GVHD prevention were performed as described previously [18] . Cytomegalovirus infection was monitored based on plasma CMV DNA using a real-time polymerase chain reaction (PCR) assay twice weekly for at least up to 12 weeks after the first infusion. Patients began preemptive therapy with ganciclovir (5 mg/ kg intravenously, twice daily) when a CMV infection was diagnosed, and this treatment was continued with the combination of foscarnet (60 mg/kg intravenously, twice daily) and immunoglobulin when the CMV infection became refractory.
Generation of Cytomegalovirus-Specific T Cells
Cytomegalovirus-specific T cells were generated as previously described [19] , with the following modifications. Peripheral blood mononuclear cells (PBMCs) were isolated from 40 mL of heparinized blood from CMV-seropositive healthy donors. Interferon γ (IFN-γ) (1000 U/mL) was added on day 0, followed 24 hours later by interleukin 2 (IL-2; 500 U/mL) and anti-CD3 antibody (100 ng/mL). On day 4 of culture, a pool of 138 synthetic pentadecapeptides (15-mers) of CMVpp65 (Miltenyi Biotec) was added as an antigen for the first stimulation. After two days of stimulation, mainly CD8 + T cells were selected, and the CMVpp65 peptide was added for a second stimulation. Cytomegalovirus-specific T cells generated as described above were further expanded in vitro for another 6-10 days, depending on whether a sufficient number (≥10 7 ) of CMV-specific T cells had been generated. Using this approach, CD8 + T cells, along with a small amount of CD4 + T cells, which included sufficient CMV-specific T cells for clinical applications, were rapidly generated.
Detection of Cytomegalovirus-Specific T-Cell Responses After Adoptive
T-Cell Transfer
To monitor the reconstitution of cellular immunity against CMV, PBMCs were collected before the first infusion and at 1, 2, 4, 8, or 12 weeks after the first infusion in the refractory cohort. As controls, PBMCs were also collected from the nonrefractory cohort and healthy donors. Notably, the times at which the PBMCs were evaluated after SCT were comparable in patients with refractory and nonrefractory CMV infection. The absolute number of CMV-specific IFN-γ + CD8 + or CD4 + T cells was determined by measuring IFN-γ production after CMVpp65-specific peptide stimulation according to published protocols [20] [21] [22] . Briefly, PBMCs (1 × 10 6 /mL) were stimulated for 6 hours with a pool of overlapping CMVpp65 peptide 15-mers (1 μg/mL; JPT, Berlin Germany) in the presence of the costimulatory monoclonal antibodies CD28 and CD49d (2 μg/ mL each; Becton Dickinson). Brefeldin A (10 μg/mL; Sigma) was added for the last 4 hours of incubation. CD107a was added at the beginning of culture when CD107a was measured. For patients (10 refractory CMV-infected patients, 14 nonrefractory CMVinfected patients, and 10 healthy donors) who had CMV pp65 epitopes NLVPMVATV (HLA-A*0201) or QYDPVAALF (HLA-A*2402), the CMV-specific T cells were also identified by staining with major histocompatibility complex (MHC) pentamers [21] .
Surface staining was performed with the following antibodies: CD3, CD4, CD8, CD45RA, CCR7, and PD-1. T-cell subpopulations were defined as follows: naive T cells (Tnaive), CD45RA + CCR7 + ; central memory T cells (Tcm), CD45RA − CCR7 + ; effector memory T cells (Tem), CD45RA − CCR7 − ; and effector T cells (Tef), CD45RA + CCR7 − [23] . For intracellular staining, fixed cells (after peptide stimulation) were incubated with IFN-γ, IL-2, tumor necrosis factor α (TNF-α), granzyme B, and perforin.
Proliferation was measured using carboxy-fluorescein succinimidyl ester (CFSE) as described with some modifications [21, 22] . Briefly, PBMCs (1 × 10 6 /mL) were labeled with 2.5 μM CFSE (Invitrogen) for 20 minutes at 37°C and blocked with 10% fetal bovine serum medium. The CFSE-labeled cells were cultured with or without pp65 peptides in the presence of IL-2 (50 IU; Sigma) and analyzed by flow cytometry after 7 days.
Definitions and Evaluation
Cytomegalovirus infection, CMV viremia, and CMV disease were diagnosed according to previously published criteria [2, 24] . Refractory CMV infection was defined as a persistent positive CMV PCR for >2 weeks despite full-dose antiviral chemotherapy [2, 9, 23, 25] . Nonrefractory CMV infection was defined as a negative CMV assay result within 2 weeks with or without antiviral drugs [14] .
Statistical Analysis
A 2-tailed Student's t test was used for normally distributed continuous variables, and the Mann-Whitney U test was used for skewed continuous variables. Statistical analyses were performed using the SPSS 22.0 and GraphPad Prism 6.0 software. P values ≤ .05 were considered statistically significant.
RESULTS
Characteristics of Patients
Patient characteristics are summarized in Tables 1 and 2 . In the refractory CMV infection cohort, the median time before CMV reactivation was 35 days (range, 22-66 days) after haplo-SCT. Ten of the 32 patients were diagnosed with CMV disease before the T-cell transfer. The median time for CMV persistence was 24 days (range, 15-94 days). The first CMVspecific T-cell treatment was infused at a median time of 69 days (range, 53-127 days) after haplo-SCT, with absolute CD8 + IFN-γ + CMV-specific T cell counts of 2.68 × 10 7 (range, 0.66-15.41 × 10 7 cells) and CD4 + IFN-γ + CMV-specific T cell counts of 1.91 × 10 5 (range, 0.68-9.25 × 10 5 cells). In the nonrefractory CMV infection cohort, all 32 patients developed only a transient CMV infection, with a median time for sustained CMV of 7 days (range, 1-12 days).
Outcome and Virological Response to Adoptive Cytomegalovirus-Specific
T-Cell Transfer
Infusion-related side effects, including cytokine release syndrome, were not observed, except for in 1 patient who developed grade 2 acute GVHD 10 days after T-cell transfer. However, this patient already had grade 1 acute GVHD before adoptive transfer; therefore, this outcome might not have been a side effect caused by the adoptive cellular therapy. Additionally, 3 of the 32 patients died during the observation period; the median time of death was 8 weeks after T-cell transfer. One patient died from post-transplant lymphoproliferative disease, another patient died from the failure of a poor graft, and a third patient died from a serious bacterial infection. However, no patient died due to CMV or transfer-related events.
The peak titer of CMV was decreased within 4 weeks after adoptive T-cell transfer in all of the treated patients except 1 ( Table 2 ). Of the 32 treated patients, 27 cleared the CMV within 4 weeks after transfer and were grouped into the early effective group. The remaining 5 patients who still experienced CMV recurrence 4 weeks after adoptive transfer were grouped into the late effective group (Table 2) . Importantly, 7 of the 10 patients with CMV disease also had controlled CMV within 4 weeks after T-cell transfer. The early and late effective groups had comparable clinical characteristics regarding patient age, underlying disease, CMV reactivation time, and CMV persistence time before the T-cell transfer. The 27 early effective patients received a total of 36 T-cell infusions, and the 5 late effective patients received a total of 11 T-cell infusions.
Association of In Vivo Cytomegalovirus-Specific T-Cell Expansion and Cytomegalovirus Clearance After Adoptive T-Cell Transfer
The quantity of CMV-specific T cells was determined before the adoptive T-cell transfer in the refractory and nonrefractory cohorts. None of the clinical characteristics, such as the time of CMV reactivation, poor graft function, history of GVHD, or anti-GVHD therapy, were significantly different between the patients with refractory and nonrefractory CMV infection. As shown in Figure 2 , both the percentage and the counts of CMV-specific CD8 + IFN-γ + T cells in the refractory cohort were significantly lower than those in the nonrefractory cohort (P = .005 and P < .001, respectively) ( Figure 2A) . Similarly, the percentage and counts of CD4 + IFN-γ + T cells were also significantly lower in the refractory cohort (P = .04 and P < .001, respectively) ( Figure 2B ). As measured by the MHC pentamer, the numbers of CMVspecific and pentamer-positive T cells were lower in the refractory CMV-infected patients, but the difference was not statistically significant (P = .41 and P = .43, respectively) ( Figure 2C ). This may due to the small number of cases detected by MHC pentamer.
The relationship between the in vivo expansion of CD8 + IFN-γ + and CD4 + IFN-γ + CMV-specific T cells and antiviral immunity is shown in Figure 3 . In the early effective group, patients who cleared viremia within 4 weeks after T-cell infusion exhibited rapid and massive in vivo expansions of CMV-specific CD8 + IFN-γ + and CD4 + IFN-γ + T cells. In contrast, in the late effective group, no significant expansion of CMV-specific CD8 + IFN-γ + or CD4 + IFN-γ + T cells was observed. Notably, CMVspecific CD8 + IFN-γ + T cell counts recovered to the level of patients with nonrefractory CMV infection in the early effective group after adoptive immunotherapy. However, CMV-specific CD4 + IFN-γ + T cell counts in the early effective group did not recover to the level of patients with nonrefractory CMV infection, which may be due to the small amount of CMV-specific CD4 + IFN-γ + T cells transferred and the slow recovery of CD4 + T cells in the early period after transplantation. Notably, after adoptive T-cell transfer, the viral load had already considerably decreased before the in vivo expansion of CMV-specific T cells.
In Vivo Expansion of Cytomegalovirus-Specific T-Cell Subpopulations After Adoptive T-Cell Transfer
We also examined subpopulations of CMV-specific T cells before and after adoptive T-cell transfer in the refractory and nonrefractory cohorts. Our data showed that in the early effective group, CMV-specific CD8 + IFN-γ + Tem and Teff cells were rare before adoptive transfer, but after the adoptive transfer, these cells quickly expanded in vivo to reach the levels present in the nonrefractory CMV-infected group ( Figure 4D ).
Functional Recovery of Cytomegalovirus-Specific T Cells After the Adoptive T-Cell Transfer
Compared with CMV-specific CD8 + T cells in the nonrefractory CMV-infected patients, cells in the refractory CMV-infected Mother-child 2 4
Child-parent 4 4
Sibling-sibling 8 9
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myelocytic leukemia; CMV, cytomegalovirus; F, female; HLA, human leukocyte antigen; M, male; N, no significant difference.
patients exhibited a reduced capacity to produce the cytokines IL-2 and TNF-α (P = .01 and P = .003, respectively) ( Figure 4A) . Notably, this deficit in the ability to produce cytokines could be reversed by adoptive transfer of CMV-specific T cells: first, significant differences were observed in IL-2 and TNF-α secretion before and after T-cell transfer in the treated patients (P < .001 and P = .004, respectively) ( Figure 4A) ; second, the levels of these cytokines for CMV-specific T cells in the treated patients increased to those observed in the nonrefractory CMV-infected patients (P = .29 and P = .86, respectively) ( Figure 4A ). We also tested the cytotoxic capacity of CMV-specific CD8 + T cells. Granzyme B and perforin secretion by CMV-specific CD8 + T cells was significantly lower in the refractory cohort than in the nonrefractory cohort (P = .047 for granzyme B and P = .03 for perforin) ( Figure 4B ). Unexpectedly, CD107a secretion by CMV-specific CD8 + T cells was comparable between the refractory and nonrefractory CMV-infected patients (P = .34) ( Figure 4B ). Adoptive T-cell transfer partially recovered the cytotoxic capacity of CMV-specific CD8 + T cells (P = .16 for granzyme B, P = .10 for perforin, and P = .50 for CD107a) ( Figure 4B ).
The proliferative capacity of CMV-specific CD8 + T cells was lower in the refractory CMV-infected patients, but the difference was not statistically significant (P = .11) ( Figure 4B) . Notably, we observed that the proliferative capacity of the CMV-specific CD8 + T cells improved after adoptive T-cell transfer (P = .03) ( Figure 4B ).
PD-1 Expression on Cytomegalovirus-Specific T Cells Decreased After Adoptive T-Cell Transfer
Refractory and persistent infections have been reported to be associated with exhausted T cells, which are characterized by a high expression of inhibitory molecules, such as PD-1 [26] [27] [28] .
In our study, we observed greater expression of PD-1 on both total CD8 + T cells (P = .01) ( Figure 5A ) and CMV-pentamerspecific T cells (P = .01) ( Figure 5B ) from the refractory CMV-infected patients than on those from the nonrefractory patients. Notably, we found that PD-1 expression decreased on the CMV-specific T cells (P = .02) ( Figure 5B) but not on total CD8 + T cells (P = .10) (Figure 5A ), after adoptive T-cell transfer.
DISCUSSION
In this prospective study, we found that (1) the adoptive transfer of CMV-specific T cells as a salvage treatment in patients with refractory CMV viremia or disease after haplo-SCT was and tumor necrosis factor α (TNF-α) production capacity (A) and cytotoxic and proliferation capacity of CD8 + CMV-specific T cells (B) among subjects with refractory CMV infection, subjects with nonrefractory CMV infection, and healthy donors. The median time for evaluating peripheral blood mononuclear cells (PBMCs) was +68 days after haploidentical stem cell transplantation (haplo-SCT; 0 weeks before adoptive T-cell transfer) and +99 days after haplo-SCT (+4 weeks after adoptive T-cell transfer) in the refractory CMV-infected patients. The median times for evaluating PBMCs were +64 days after haplo-SCT and +92 days after haplo-SCT in the nonrefractory CMV-infected patients. The data are all shown as the means ± standard error of the mean. Abbreviations: CFSE, carboxy-fluorescein succinimidyl ester; CMV, cytomegalovirus; HD, healthy donor; IL-2, interleukin 2; TNF-α, tumor necrosis factor α.
safe and efficacious, (2) the adoptive transfer of CMV-specific T cells reconstitutes specific antiviral immunity by improving the quantity and function of CMV-specific T cells, and (3) the recovery of CMV-specific T-cell function might be due to the reversion of T-cell exhaustion. A few phase I-II studies have established that the application of CMV-specific T cells can reconstitute specific viral immunity and protect patients from CMV-related complications [6, 7, 10, 29, 30] . However, little is known about the behavior of CMV-specific T cells in adoptive therapy after haplo-SCT. In our study, we prospectively investigated the therapeutic application of donor-derived CMV-specific T cells in 32 patients who suffered from refractory CMV infection after haplo-SCT. To the best of our knowledge, this represents the largest study conducted to date examining the clinical utility of CMV-specific T cells administered for CMV infection after haplo-SCT.
It is widely accepted that the reconstitution of CMV-specific T cells after SCT is correlated with the control of CMV infection [31, 32] . We observed significantly fewer CMV-specific CD8 + IFN-γ + and CD4 + IFN-γ + T cells in the refractory CMV-infected patients than in the nonrefractory CMV-infected patients. After adoptive T-cell transfer, we observed the in vivo expansion of CMV-specific T cells. Based on a comparison of the immune recovery in the early and late effective subgroups, we confirmed that the rapid and massive in vivo expansion of CD8 + and CD4 + CMV-specific T cells is closely associated with CMV clearance. Our results are consistent with previous studies, which emphasized that the survival of adoptively transferred CMV-specific T cells is associated with long-term protection against CMV infection; however, only limited data are available from a relatively small number of cases [7, 9, 11] . In addition to quantity, we also examined the function of CMV-specific T cells. As documented by others, the exhaustion of T cells, including virus-specific T cells, can be observed in patients with refractory and persistent viral infections, such as human immunodeficiency virus or hepatitis B virus. However, whether the exhaustion of T cells occurs in cases of refractory CMV infection remains controversial [13, 27, 33, 34] . Recently, some studies have supported the idea that the exhaustion of T cells in patients with CMV disease or refractory CMV infection occurs after allo-SCT. Gallez-Hawkins et al [33] reported that high PD-1 expression on the entire population of CD4 + and CD8 + T cells, and not on CMV-specific T cells alone, was correlated with CMV disease after allo-SCT. Kato et al [14] demonstrated the exhaustion of CMV-specific T cells based on the enhanced expression of the inhibitory molecule PD-1 in refractory CMV infection after allo-SCT. Consistent with their findings, we observed the impairment of CMV-specific T cells, which was characterized by a low cytokine production capacity, low cytotoxic ability, and high expression of PD-1, in patients with refractory CMV infection after haplo-SCT. Intriguingly, we found that the adoptive transfer of CMV-specific T cells could reverse such an impairment. To the best of our knowledge, this represents the first study to explore the ability of treatment with CMV-specific T cells to reverse T-cell impairment in recipients with refractory CMV infection. The molecular mechanisms that drive this phenomenon remain to be further examined.
There are several limitations to this study. First, although this study includes the largest number of haplo-SCT recipients treated with CMV-specific T cells to date, it is a single-arm study that was performed only in our center. Second, it might be better to have another arm that consisted of refractory and persistent CMV-infected patients treated only with antiviral drug. However, cellular adoptive immunotherapy has proven efficacious for the treatment of CMV infection after transplantation. Thus, for ethical reasons, we could not have a randomly selected control group in which refractory and persistent CMV-infected patients continued treatment with just a standard antiviral drug. Furthermore, the remaining refractory CMV-infected patients who did not receive CMV-specific T cells for clinical reasons could not be selected as control subject because the pre-, peri-, and post-transplant characteristics were not comparable with those of the patients receiving adoptive T-cell transfer. Third, because all of the transferred T cells were from the primary stem cell donor, we could not easily detect how these transferred cells expanded and where the cells persisted in vivo. Further studies using a humanized mouse model may be helpful to answer these questions. Fourth, refractory CMV infection is defined by clinical resistance to antiviral drugs [25, 35] , and none of the patients in our study were tested for specific genetic mutations for either ganciclovir or foscarnet resistance.
In conclusion, the adoptive transfer of donor-derived CMVspecific T cells is safe and efficient in eliminating refractory CMV viremia and disease after haplo-SCT. We provide important insights into the reconstitution of long-term antiviral immunity associated with the in vivo expansion of CMV-specific T cells and the functional recovery of CMV-specific T cells.
Notes
